Lenalidomide Sun (Lenalidomide)

• Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones.
• Multiple Myeloma: Reduces disease progression and improves survival in adult patients.
• Myelodysplastic Syndromes: Decreases transfusion dependence and modifies disease course in patients with del(5q) cytogenetic abnormality.
• Mantle Cell Lymphoma: Provides therapeutic benefit in relapsed or refractory disease.

• Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), leading to reduced proliferation of malignant plasma cells, enhanced immune‑mediated tumor cell killing, and inhibition of angiogenic factors. The combined immunomodulatory, anti‑angiogenic, and direct anti‑myeloma actions underlie its therapeutic effect.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: Persistent tiredness affecting daily activities.
• Nausea: Stomach upset often occurring after dosing.
• Diarrhea: Loose stools that may be mild to moderate.
• Rash: Skin redness or itching.

Serious or Rare Side Effects

• Neutropenia: Significant reduction in neutrophil count increasing infection risk.
• Thromboembolic events: Deep vein thrombosis or pulmonary embolism.
• Teratogenicity: Potential to cause fetal malformations; contraindicated in pregnancy.

• When prescribing Lenalidomide, clinicians should observe several safety considerations.
• Pregnancy: Contraindicated; use effective contraception for both patient and partner.
• Thrombosis risk: Assess and manage pre‑existing clotting disorders; consider anticoagulation.
• Renal impairment: Adjust dosing and monitor renal function closely.
• Hematologic monitoring: Perform regular complete blood counts to detect cytopenias.
• Infection vigilance: Monitor for signs of infection and treat promptly.
• Store at ambient temperature: Keep below 25 °C in the original container, protected from moisture and light.

Lenalidomide interacts with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): May reduce lenalidomide exposure, compromising efficacy.
• Anticoagulants (e.g., warfarin): Increased risk of bleeding; concurrent use should be avoided.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine): May enhance immunosuppression, monitor infection signs.
• Vaccines: Live attenuated vaccines may be less effective; avoid during therapy.
• Contraceptives: Hormonal methods may have reduced effectiveness; advise additional barrier methods.